Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. - Wikidata - wikimedia - TriplyDB

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

http://www.wikidata.org/entity/Q51807138

about

The significance of markers in the diagnosis of endometrial cancer Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.Molecular profiling of endometrial malignancies.Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas Signalling pathways in endometrial cancer Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.Molecular staging of gynecological cancer: What is the future?The genomics and genetics of endometrial cancer.Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma Features of endometrial cancer in patients with 'metabolically healthy' versus 'standard' obesity: the decreasing frequency of metabolically healthy obesity Emerging therapeutic targets in endometrial cancer.Endometrial carcinoma: molecular alterations involved in tumor development and progression.High-grade endometrial carcinomas - strategies for typing.Molecular pathology of endometrial carcinoma.Current status of molecular biomarkers in endometrial cancer.PI3K/Akt-mediated regulation of p53 in cancer.Molecular alterations in endometrial archived liquid-based cytology.Analysis of differentially expressed genes between endometrial carcinosarcomas and endometrioid endometrial carcinoma by bioinformatics.PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.Proteomics of endometrial cancer diagnosis, treatment, and prognosis.Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.Molecular analysis of isolated tumor glands from endometrial endometrioid adenocarcinomas.

P2860

Q28067066-1EF1BAF9-C4F5-4B64-82E4-51564F6652FE Q30492318-30AE7665-0BFB-459C-8652-B8296CC4D490 Q33757898-85F9C79A-8457-4310-8EA1-304A9797A04C Q33899157-5FCA07C7-C525-41DF-91F6-93DF17B4F233 Q34039589-A3910A1D-BEBA-4595-B6A0-5845E81151FA Q34458796-B42149BF-E8E8-4D38-BC9C-83C7289D74C0 Q34574472-50A4D7B7-985F-476B-8352-A6DDFE345C3F Q34694344-B77CEE44-ECC2-4DB8-AFA3-565FBB53AFB4 Q34721660-CD971374-713E-4F88-A4E0-AB524702D5A7 Q35172203-7189D0BE-D583-40DF-B46A-26CF9934AB4B Q35886886-9AD930D0-3F75-4762-A31D-4B071909CCF1 Q35940829-197521B8-568D-45C3-808E-F96F1ACF0EA3 Q36151896-F03C756B-1743-4CB8-9A29-2D6579D05E64 Q36354855-7F35ABA1-EB4B-4B06-B76A-527949A17D2B Q36386468-83A6C6C2-9BEF-4311-A29C-E50AAC83575A Q36418630-28C3D873-DA0E-4DC9-8074-3827B0A7EA0B Q36477469-4C0E51CD-1FE1-4E0E-B8C9-56FCB4546B3A Q36857470-67FEB0BE-D861-4BB7-A169-DAEFF3F3A526 Q37038863-06277787-7D6E-4F43-A349-A85F789CF23E Q37376449-DC3AF125-DCEB-44A7-9624-16AA021D1F6D Q37432375-3785F29F-E10E-43C0-9AD1-FA5F6083E7AC Q37474382-B9F411B6-797A-41EB-8DD5-EF286BE0770D Q37827340-AC6F83C0-0D47-48C8-9A3C-7E173CCBD1F5 Q37994980-8EA70BA0-0257-4AE7-A0C7-66484E30C82D Q38067439-A4A98768-A64E-46FC-B4EA-4AD5B00CCF79 Q38067440-F46F7809-17A7-4BDE-9351-B60DA989BD3C Q38234228-40D1804F-CD7C-4E7F-9066-A0ACE01CBA48 Q38238609-E2458FAA-BCED-47D1-BBE9-6410B8808EB2 Q38402223-A1D306FE-4E60-4866-A079-EE32202181FA Q38457773-0F1FFD52-EF0D-48ED-8FCF-1E0017B41407 Q38599066-C626F789-B6E6-4426-881A-C8F1E3EA3904 Q38626386-585DA736-8D8C-4B62-BC04-9B6A7B3C9FEB Q38725254-CEF1B98C-A3BD-495D-9132-8B7AE5A31F38 Q38798466-6C6BF02C-3443-49E4-9C54-9A42647E35A2 Q38984603-B4447396-14D3-4919-99BE-A5BB33834A39 Q39406462-7F3601D0-58D0-46EB-829C-90B505636FB9 Q39418221-4D77A5CA-F5BC-49B2-B46D-BF69BA98678B Q39644716-E8E5901C-72AF-4876-B5E1-23C1085EF90D Q39898816-591110AA-2250-4E45-A11E-7CCF8A6EF5B1 Q41138341-C70916E1-ECC2-4F63-AE6B-3FC8EF46CF60

P2860

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

http://www.wikidata.org/entity/Q51807138

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@en

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@nl

type

label

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@en

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@nl

prefLabel

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@en

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@nl

P1433

Q51807138-164A32C0-70B7-4BF4-89EF-62524CA5E918

P1476

Q51807138-4F1A17FF-3337-433B-8138-DAC2CFD86D7F

P2093

Q51807138-0F1CF725-B883-45B1-9B25-940590E20500

Q51807138-628B3E6F-D245-4E5E-9275-767CE21BA5B4

Q51807138-FA175274-3A8F-4EFD-B786-871C74060D67

P2860

Q51807138-0D41F9E4-BBB7-496F-A869-7D9DF22F6C42

Q51807138-1319554A-ABC2-4E14-9697-D83CE96B35C1

Q51807138-178143D0-F2DA-449B-ADDD-7A009741EFDE

Q51807138-1CE91AB8-BE5D-42D9-9769-65491F6EE71B

Q51807138-46A10773-3652-462D-8E48-F4AFA9A3E77C

Q51807138-47DAECEF-AB2C-4C6E-ACB1-D47073613B25

Q51807138-4ED56C53-4DB8-414D-9885-CF57C507009E

Q51807138-5722DB76-A30A-41A7-AD3A-711152C5FEE4

Q51807138-6BF183AC-22F4-456D-9E06-C274BE22A6FE

Q51807138-7C457ECF-8F9C-4B09-AE4C-38C78F05A4CE

P2888

Q51807138-855FD80F-A736-41DE-928E-F0588EAF9AC9

P304

Q51807138-8345E10C-9D55-45E9-975D-154428DCEA43

P31

Q51807138-CDCDF4E4-F0B3-4F38-B4DF-B4A1AB23235E

P356

Q51807138-1D82CBC7-D959-42C5-BC0E-E4E7F047E566

P433

Q51807138-7F3809A4-098A-49B1-A689-364F7FD89B4B

P478

Q51807138-F329B460-32EF-4756-A5E3-2C25C97EB8F7

P50

Q51807138-794D04A6-27D3-4C54-AE7B-7598C284CA6B

P577

Q51807138-9353E3A2-090B-4C76-AF67-741139DD5DE5

P5875

Q51807138-72EE1FFC-82CA-40F2-A424-97DC58452E17

P698

Q51807138-8F19DCC8-43BA-4B8D-A476-16FE1E12AD3B

P356

MODPATHOL.2009.5

P1433

Modern Pathology

P1476

Concomitant PI3K-AKT and p53 a ...... ssociated with poor prognosis.

@en

P2093

Jaime Prat

http://www.w3.org/2001/XMLSchema#string

Lluis Catasus

http://www.w3.org/2001/XMLSchema#string

Miriam Cuatrecasas

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

High frequency of mutations of the PIK3CA gene in human cancers

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

Regulation of PTEN transcription by p53

Cancer-specific mutations in PIK3CA are oncogenic in vivo

Two pathogenetic types of endometrial carcinoma.

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Rare cancer-specific mutations in PIK3CA show gain of function

P2888

modpathol.2009.5

P304

522-529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2009.5

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Gallardo

P577

2009-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24032222

http://www.w3.org/2001/XMLSchema#string

P698

19234438

http://www.w3.org/2001/XMLSchema#string